scholarly journals Weight loss for women with and without polycystic ovary syndrome following a very low-calorie diet in a community-based setting with trained facilitators for 12 weeks

2015 ◽  
pp. 495 ◽  
Author(s):  
Efsevia Nikokavoura ◽  
Kelly L Johnston ◽  
John Broom ◽  
Wendy Wrieden ◽  
Catherine Rolland
Keyword(s):  
Weight Loss ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Very Low Calorie Diet ◽  
Community Based ◽  
Ovary Syndrome ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

scholarly journals Vegan or Low Calorie Diet for Weight Loss in Polycystic Ovary Syndrome Females: A Randomised Controlled Study

2020 ◽  
Vol 14 (1-2) ◽  
Author(s):  
Shubhra Saraswat
Keyword(s):  
Weight Loss ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Randomized Study ◽  
Vegan Diet ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

ABSTRACT The primary aim of this randomized study is to find the effect of a diet based intervention (vegan diet and low-calorie diet) among women suffering from polycystic ovary syndrome (PCOS). Overweight and obese (BMI- 33.7 ± 4.8 kg/m2) women with PCOS (n = 21; age, 33.1 ± 4.4 years) were assessed to participate in a 90 days randomized weight loss study delivered and guided through diet and nutrition counseling (personalized and group). Body weight, BMI and waist circumference and dietary intakes were assessed three times at 0, 45 and 90 days. It was hypothesized that weight loss would be more in the vegan group. All data were statistically analyzed and presented as median (inter quartile range). Vegan participants reported significant weight loss at Day 90, “1.8% (“5.0%, “0.9%) vegan, 0.0% (“1.2%, 0.3%) low-cal; P = .04), Vegan participants showed a greater decrease in energy (“265 (“469, 0)) kcal/d) and fat intake “8.2% (“9.8%, 0%) energy) at Day 90 compared with low-cal participants (0 (0, 173)) kcal/d, P = .02; 0 (0, 3.7%) energy, P = .02). The results suggest that following a vegan diet can be more effective for achieving weight loss in addition to better nutrient intake profile in women with PCOS; however, a bigger sample size is required to validate these results.

scholarly journals The experiences of women with polycystic ovary syndrome on a very low-calorie diet

2016 ◽  
Vol Volume 8 ◽  
pp. 299-310 ◽  
Author(s):  
John Love ◽  
John McKenzie ◽  
Efsevia Anastasia Nikokavoura ◽  
Iain Broom ◽  
Catherine Rolland ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Very Low Calorie Diet ◽  
Ovary Syndrome ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Experiences Of Women

scholarly journals Efficacy of Octreotide-LAR in Dieting Women with Abdominal Obesity and Polycystic Ovary Syndrome

2005 ◽  
Vol 90 (7) ◽  
pp. 3854-3862 ◽  
Author(s):  
Alessandra Gambineri ◽  
Laura Patton ◽  
Rosaria De Iasio ◽  
Barbara Cantelli ◽  
Graciela Estela Cognini ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Outcome Measures ◽  
Polycystic Ovary ◽  
Fat Distribution ◽  
Ovary Syndrome ◽  
Octreotide Lar ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Igf I ◽  
Calorie Diet

Abstract Context: Somatostatin reduces LH, GH, and insulin, and somatostatin receptors are present at the ovarian level; somatostatin analogs are thus potential candidates for treatment of the polycystic ovary syndrome (PCOS). Objective: The purpose of this study was to evaluate the effect of octreotide-LAR, a long-acting somatostatin analog, in anovulatory abdominal obese women with PCOS. Design: A single-blind, placebo-controlled study was performed, lasting for 7 months. Setting: The patients were ambulatory throughout the study. Patients: Twenty PCOS subjects were enrolled. Eighteen completed the study. Interventions: A low-calorie diet was given during the first month, a low-calorie diet plus octreotide-LAR (10 mg; n = 10 subjects) or placebo (n = 10 subjects) was then given, with one im injection every 28 d (for 6 months). Main Outcome Measures: The main outcome measures were clinical features, computerized tomography measurement of fat distribution, androgens, GH, IGF-I, IGF-binding proteins (IGFBPs), fasting and glucose-stimulated insulin, and ovulation. Results: Octreotide had no additional effect in reducing body fat or improving fat distribution than placebo. Conversely, octreotide produced an additional decrease in fasting (P = 0.018) and glucose-stimulated (P = 0.038) insulin levels, an increase in IGFBP-2 (P = 0.042) and IGFBP-3 (P = 0.047), and an improvement in hirsutism (P = 0.004). Moreover, a trend toward greater reductions in testosterone (P = 0.061) and androstenedione (P = 0.069) was observed in women treated with octreotide-LAR compared with those given placebo. All women treated with octreotide ovulated at the end of the study compared with only one of those receiving placebo (P < 0.001). Conclusions: Octreotide-LAR may be usefully applied to hypocalorically dieting, abdominal obese PCOS women to improve hyperandrogenism and the insulin-IGF-I system. Restoration of ovulatory menstrual cycles appears to be another advantage of this treatment.

scholarly journals A Low Glycemic Index Decreases Inflammation by Increasing the Concentration of Uric Acid and the Activity of Glutathione Peroxidase (GPx3) in Patients with Polycystic Ovary Syndrome (PCOS)

Molecules ◽  
2019 ◽  
Vol 24 (8) ◽  
pp. 1508 ◽  
Author(s):  
Małgorzata Szczuko ◽  
Marta Zapalowska-Chwyć ◽  
Radosław Drozd
Keyword(s):  
Uric Acid ◽  
Polycystic Ovary Syndrome ◽  
Glutathione Peroxidase ◽  
Glycemic Index ◽  
Dietary Intervention ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

Introduction: According to a review of the literature, there is a lack of data on the mechanisms that participate in the suppression of inflammation that accompanies polycystic ovary syndrome (PCOS). Additionally, the changes in oxidative status resulting from a low-calorie diet have not been studied in a group of women with PCOS, and the oxidation and reduction processes associated with PCOS have not been explained. Material and methods: The study involved 49 women who were diagnosed with PCOS according to Rotterdam’s criteria, and 24 women voluntarily agreed to a three-month dietary intervention. The dietary intervention was carried out for 3 months. Glutathione peroxidase (GPx3) activity, the Ferric reducing ability of plasma, and uric acid concentration were measured spectrophotometrically both before and after the intervention. Statistical analysis was performed with the Statistica 10.0 software package, and a Pearson’s correlation matrix was generated. Results: A lower concentration of GPx3 was observed in women with PCOS (before the dietetic intervention began) compared with the GPx3 levels in healthy women. A relationship was shown between GPx3 levels and the concentration of prolactin, insulin on fasting, and triglycerides. After the dietary intervention, increases in uric acid and GPx3 activity were noted, as well as numerous relationships between anthropometric and biochemical parameters. The ferric reducing/antioxidant power did not change significantly. Conclusions: Inhibiting the effect of prolactin (by the level of reactive oxygen species) on the activity of GPx3 could be a starting point for the increase in antioxidative stress and the development of the inflammatory state associated with PCOS pathophysiology. Following a low-calorie diet with a lower glycemic index is proposed to silence inflammation by increasing the concentration of uric acid. During GPx3 mobilization, women with PCOS have a higher demand for selenium, and its deficiencies may contribute to disordered thyroid hormone synthesis. The three-month dietary intervention did not silence redox processes in the examined group of women.

Effectiveness, Compliance, and Acceptability of Preoperative Weight Loss with a Liquid Very Low-Calorie Diet Before Bariatric Surgery in Real Practice

2018 ◽  
Vol 29 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Kamthorn Yolsuriyanwong ◽  
Komdej Thanavachirasin ◽  
Kimberly Sasso ◽  
Lauren Zuro ◽  
Jessica Bartfield ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Preoperative Weight Loss ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Preoperative Weight ◽  
Real Practice

scholarly journals Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Good Clinical Practice ◽  
Study Groups ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32

Sign in / Sign up

Export Citation Format

Share Document